Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Completed Initiated Sep 24, 2019 (7 years ago)

Rite Aid Pharmacy Maximum Strength Ranitidine Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

GGMP Deviations: Possible contamination with impurity N-nitrosodimethylamine (NDMA).

Cause type: Nitrosamine impurity

Trace nitrosamine impurities such as NDMA, NDEA or NMBA found above the acceptable daily limit. Nitrosamines are probable human carcinogens that can form during manufacturing or storage. This is the cause behind the large valsartan, losartan and ranitidine (Zantac) recalls. All nitrosamine impurity recalls.

What was recalled

Rite Aid Pharmacy Maximum Strength Ranitidine Tablets, USP 150 mg Cool Mint Acid Reducer 24 Tablets Sugar Free NDC 11822-6107-4 Distributed By: Rite Aid 30 Hunter Lane, Camp Hill, PA 17011

Affected NDC 11822-6107-04

Compare with the code on your package — it is the most precise check available.

Drug: Ranitidine Category: Heartburn & Stomach Medication

Recalling firm
Apotex Inc.
NDC code
11822-6107-4
Origin
N/A, Canada
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0317-2020 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now completed, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Ranitidine recalls

See all
Class II · Moderate risk

Ranitidine 300 mg

CGMP Deviations: Presence of NDMA impurity detected in product.

Terminated Nitrosamine impurity Direct Rx NDC 61919-455-30 D-0017-2021
Class II · Moderate risk

Ranitidine 150 mg

CGMP Deviations: Presence of NDMA impurity detected in product.

Terminated Nitrosamine impurity Direct Rx NDC 61919-339-60 D-0016-2021
Class II · Moderate risk

ranitidine hydrochloride

CGMP Deviations: Received notice from supplier of potential -Nitrosodimethylamine (NDMA) amounts above established levels.

Terminated Nitrosamine impurity PD-Rx Pharmaceuticals, Inc. NDC 43063-844-14 D-0826-2020

Other recalls by Apotex Inc.

All 2019 recalls
Class II · Moderate risk

Paxil CR

Failed Dissolution Specifications; product failed to meet 24-month stability testing acceptance criteria

Ongoing Dissolution failure Apotex Corp. NDC 60505-4379-3 D-0804-2026
Class II · Moderate risk

Desmopressin Nasal Spray

Defective container: defect in a batch of bottle caps, specifically involving dislodged or missing cap liners.

Ongoing Packaging defect Apotex Corp. NDC 60505-0815-0 D-0510-2026